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LETTER
Exome sequencing reveals a
novel partial deletion in the
progranulin gene causing
primary progressive aphasia
In 2005, we reported a case of familial
primary progressive aphasia (PPA) in this
journal.1 The individual in question had a
family history of frontotemporal dementia
(FTD), her brother having behavioural
variant FTD shown to be due to tau-
negative, ubiquitin-positive (FTLD-U)
pathology at postmortem. She was fol-
lowed as part of a research programme
from the age of 51 years, ﬁrst developing
symptoms of progressive speech disturb-
ance at the age of 55 years. We were able
to demonstrate the emergence of neurop-
sychometric deﬁcits and brain atrophy
prior to symptom onset. Through the use
of voxel compression mapping, we
showed the emergence of very focal,
presymptomatic regional atrophy initially
almost entirely conﬁned to the pars oper-
cularis (ﬁgure 1A).1 Over time, the
atrophy spread through the frontal and
temporal lobes to affect the parietal lobe
and then the right frontal lobe.
Subsequent analysis has shown increase in
left and right hemispheric lobar atrophy
prior to symptom onset, although the
left hemisphere volume loss preceded
and remained more prominent than the
right throughout the disease course
(ﬁgure 1B).
At the time of publication, mutations in
the microtubule-associated protein tau
(MAPT) were the only known genetic
cause of disorders within the FTD spec-
trum, and screening for MAPT mutations
was negative. Since then, the progranulin
(GRN) and C9ORF72 genes have been
shown to be major causes of familial
FTD.2 Her brother’s pathology was subse-
quently reanalysed and reclassiﬁed as
FTLD-transactive response DNA-binding
protein (TDP) type A pathology,3 consist-
ent with either a GRN or C9ORF72
mutation. However, conventional analyses
failed to disclose mutations in either of
these genes in this family.4–6
In order to investigate this further, DNA
from her brother underwent exome sequen-
cing, performed on genomic DNA using
Agilent SureSelect Human All Exon v2
target enrichment kit. Sequencing was per-
formed on an Illumina HiSeq2000 and
achieved an average 30-fold depth-of-cover-
age of target sequence.7 ExomeDepth8
compares the read depth data between a
test sample and an aggregate reference set
that combines multiple exomes matched to
the test sample for technical variability
(Software freely available at: http://cran.
r-project.org/web/packages/ExomeDepth/
index.html). Analysis demonstrated a GRN
gene deletion. The red crosses (ﬁgure 2)
show the ratio of observed/expected
number of reads for the test sample. The
grey shaded region shows the estimated
99% CI for this observed ratio in the
absence of copy number variation (CNV)
call. The presence of contiguous exons with
read count ratio located outside of the CI is
indicative of a heterozygous deletion in the
GRN gene. GRN exons 0, 2, 5, 9 and 11
were subsequently probed for copy number
variation using multiplex ligation-
dependent probe ampliﬁcation (MLPA)
analysis with the Medical Research Council
(MRC) Holland kit P275, which is rou-
tinely used for assessing GRN deletions.9 10
This conﬁrmed the presence of a novel het-
erozygous deletion of exons 2–11. Test
results show the 50 untranslated region of
the gene was present, but could not deter-
mine if exon 12 of GRN was also deleted.
The same deletion was detected in the
proband using MLPA analysis.
While progranulin mutations were not
known to cause frontotemporal lobar
degeneration at the time of our original
report, the clinical features that emerged
during the course of her illness would now
be recognised as being fairly characteristic.
Progranulin mutations are usually asso-
ciated with behavioural variant FTD or
PPA,2 3 with combinations of these presen-
tations recognised within the same family.
Neuropsychologically, patients often have
executive dysfunction and early parietal
lobe deﬁcits, with PPA patients having a
non-ﬂuent aphasia with a prominent
anomia. Imaging studies in patients with
established disease typically show promin-
ent asymmetrical atrophy affecting frontal,
temporal and parietal lobes consistent with
neuropsychological ﬁndings.11 Finally, the
pathology, type A TDP-43, would be con-
sistent with that seen in progranulin muta-
tions (and also C9ORF72 expansions).2 3
This case serves to illustrate a number
of important points. First, progranulin
Figure 1 MRI changes in the proband: (A) sagittal MRI showing focal anterolateral left frontal lobe atrophy, particularly centred around the pars
opercularis, using voxel compression mapping between the ﬁrst and second scans (3.4 and 2.1 years prior to symptom onset) (reprinted from
Janssen et al,1; (B) changes in left and right hemispheric volume over time.
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mutations should always be considered as
a cause of PPA where there is a positive
family history either of PPA or behav-
ioural variant FTD. Second, prominent
asymmetric lobar atrophy on MRI is an
important clue to the presence of a pro-
granulin rather than a MAPT or
C9ORF72 mutation in the context of an
autosomal-dominant family history. Third,
as with other neurodegenerative diseases,
this case shows that focal brain atrophy
precedes symptom onset in genetically
determined forms of FTD; rates of
atrophy may therefore be useful outcome
measures for presymptomatic therapeutic
trials in these disorders. Finally, the fact
that conventional progranulin testing was
negative in this case demonstrates the
power of exome sequencing as a tool to
discover large-scale mutations, such as the
partial deletion seen here, that may not be
found with usual screening methods for
small-scale changes.
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Figure 2 The read count ratio of observed to expected is shown plotted against position in
basepairs along chromosome 17. A reduction in read count ratio to 0.5 and below at the GRN
locus can be seen, and indicate a heterozygous gene deletion.
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